

PRESS RELEASE

New Experimental Medicine in EHEC

Bunnik, The Netherlands, June 7, 2011.

Dutch biopharmaceutical company Alloksys Life Sciences has an experimental medicine which might help to counteract the effects of an EHEC infection.

“We now have over 10 years scientific research data on various acute inflammatory diseases. Multiple placebo controlled double-blind clinical studies show that Alkaline Phosphatase, acting as gatekeeper to the immune system, inactivates the inflammatory factors. This will prevent a cascade of inflammatory responses, where in particular the intestines and kidneys will be protected. Based on this mechanism of action, we expect Alkaline Phosphatase could also help to combat the effects of EHEC infection”, according to Prof. Dr. Willem Seinen.

With the increase of severely affected patients, some hospitals deal with overflowing Intensive Care Units. Precisely for these patients it is expected that the experimental medicine can help to prevent complications. The product is proven to be safe in clinical trials involving more than 100 patients and can be available at short term.

More information can be found on www.alloksys.com

About Alkaline Phosphatase

Alkaline Phosphatase is an enzyme that is naturally present in the liver, kidneys and intestines. A shortage of Alkaline Phosphatase occurs in inflammatory conditions and diseases, which causes continuation of inflammatory reactions. By administering Alkaline Phosphatase the inflammatory factors can be inactivated and complications can be avoided.

About Alloksys Life Sciences www.alloksys.com

Alloksys Life Sciences is a biopharmaceutical company that focuses on the treatment of acute and chronic inflammatory diseases. The most advanced application is in heart valve surgery and is in Phase IIIa. In chronic inflammatory diseases, the primary focus is on the treatment of rheumatoid arthritis.